<DOC>
	<DOCNO>NCT02829385</DOCNO>
	<brief_summary>This study make observation objective response rate Apatinib XELOX combination regimen first-line treatment metastatic colorectal cancer . All participant receive treatment Apatinib XELOX combination regimen .</brief_summary>
	<brief_title>Clinical Study Apatinib XELOX Combination Regimen Treat Colorectal Cancer Patients</brief_title>
	<detailed_description>XELOX chemotherapy effective therapy metastatic colorectal cancer first-line treatment . Apatinib small-molecule tyrosine kinase inhibitor ( TKI ) highly selectively bind strongly inhibit vascular endothelial growth factor receptor 2 ( VEGFR-2 ) , decrease VEGF-mediated endothelial cell migration , proliferation , tumor microvascular density . A phase II trail Apatinib demonstrate Apatinib safe treat metastatic colorectal cancer disease control rate reach 50 % .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Unresectable colorectal cancer confirm histological mean measurable indication（a minimum size 10mm spiral CT scan，which meet criteria RECIST 1.1） . Time interval trace back late administration xelox folfox combination must less 1 year . age range : ≥18 ≤75 . ECOG PS scale 0 1；expected survival time ≥12 week . Sufficient blood function：absolute neutrophil count ( ANC ) ≥1.5×109/L , platelet count ≥80×109/L hemoglobin≥9g/dL . Sufficient hepatic function：total bilirubin ≤1.5 time upper normal limit ( ULN ) , AST ≤2.5 time ULN , ALT ≤2.5 time ULN AKP ≤5 time ULN . *AST , ALT relevant criterion alters AST ≤5 time ULN ALT ≤5 time ULN hepatic metastasis . sufficient renal function : serum creatinin ≤ULN , creatinine clearance rate ≥60 mL/min Female patient age 50 complete uterus must test negative pregnancy within 28 day enrollment ( except suffer amenorrhea 24 month ) . If pregnancy test carry 7 day first administration , urine pregnancy test require validation . ( within 7day interval administration ) Informed consent subscription . ( The consent approve independent Ethics Committee , sign patient substantial trial initiate . ) Have get malignant tumor within last 5 year , exclude basal cell skin cancer cervical carcinoma situ already cure . With evidence CNS metastasis , even treatment carry , patient doubt CNS metastasis conduct MRI enhance CT scan within 28 day enrollment ruling . AST ≤2.5 time ULN and/or ALT ≤2.5 time ULN Had treat chemotherapy last 12 month Had treat radiotherapy ( except palliative radiotherapy evaluable focus outside radiotherapy field purpose alleviate pain ) With uncontrolled systemic disease , include active infection , hypertension without treatment , diabetes mellitus , angina pectoris , congestive heart failure , myocardial infarction , severe arrhythmia require treatment hepatic/renal/metabolic diseases Taking experimental treatment another clinical trial study . Being allergic relevant chemotherapy drug . With evidenceproved disease , neural metabolic disorder , physical lab examination abnormality , might contraindication study drug lead treatingrelated lethal complication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Apatinib</keyword>
	<keyword>XELOX Regimen</keyword>
	<keyword>metastatic colorectal cancer</keyword>
</DOC>